AIMS/HYPOTHESIS: We investigated the association of variants of the transcription factor 7-like 2 (TCF7L2) gene with: (1) incident diabetes in the Finnish Diabetes Prevention Study (DPS, Study I); (2) type 2 diabetes and impaired glucose regulation (i.e. IGT or IFG) in a cross-sectional study (Study II); and (3) insulin secretion, insulin sensitivity and adipose tissue expression of TCF7L2 in offspring of type 2 diabetic probands (III). SUBJECTS AND METHODS: Study I (the DPS) included 507 individuals with IGT who were randomly allocated to control and intervention groups and followed for an average of 3.9 years to monitor for progression to diabetes. Study II was a population-based cross-sectional study of 1,766 men, aged 50-70 years, randomly selected from the population of Kuopio, eastern Finland. Study III included 238 non-diabetic offspring of patients with type 2 diabetes. Genotyping of rs12255372 and rs7903146 of TCF7L2 was carried out. RESULTS: In the DPS, the TT genotype of rs12255372 was significantly associated with an adjusted 2.85-fold risk (95% CI 1.17-6.95, p = 0.021) of incident diabetes in the control group, but not in the intervention group. In Study II, the adjusted odds ratio in subjects with the TT genotype was 3.40 (1.45-7.97, p = 0.005) for the comparison of diabetic subjects with normoglycaemic subjects. The T allele of rs12255372 was significantly associated with decreased insulin secretion (Studies II, III). Expression of TCF7L2 in adipose tissue tended to be lower in subjects with the TT risk genotypes of rs12255372 and rs7903146. CONCLUSIONS/ INTERPRETATION: The variant of rs12255372 of TCF7L2 was associated with incident type 2 diabetes in the DPS and in a separate population-based cross-sectional study. Impaired insulin secretion is likely to be the main cause for our findings.
RCT Entities:
AIMS/HYPOTHESIS: We investigated the association of variants of the transcription factor 7-like 2 (TCF7L2) gene with: (1) incident diabetes in the Finnish Diabetes Prevention Study (DPS, Study I); (2) type 2 diabetes and impaired glucose regulation (i.e. IGT or IFG) in a cross-sectional study (Study II); and (3) insulin secretion, insulin sensitivity and adipose tissue expression of TCF7L2 in offspring of type 2 diabetic probands (III). SUBJECTS AND METHODS: Study I (the DPS) included 507 individuals with IGT who were randomly allocated to control and intervention groups and followed for an average of 3.9 years to monitor for progression to diabetes. Study II was a population-based cross-sectional study of 1,766 men, aged 50-70 years, randomly selected from the population of Kuopio, eastern Finland. Study III included 238 non-diabetic offspring of patients with type 2 diabetes. Genotyping of rs12255372 and rs7903146 of TCF7L2 was carried out. RESULTS: In the DPS, the TT genotype of rs12255372 was significantly associated with an adjusted 2.85-fold risk (95% CI 1.17-6.95, p = 0.021) of incident diabetes in the control group, but not in the intervention group. In Study II, the adjusted odds ratio in subjects with the TT genotype was 3.40 (1.45-7.97, p = 0.005) for the comparison of diabetic subjects with normoglycaemic subjects. The T allele of rs12255372 was significantly associated with decreased insulin secretion (Studies II, III). Expression of TCF7L2 in adipose tissue tended to be lower in subjects with the TT risk genotypes of rs12255372 and rs7903146. CONCLUSIONS/ INTERPRETATION: The variant of rs12255372 of TCF7L2 was associated with incident type 2 diabetes in the DPS and in a separate population-based cross-sectional study. Impaired insulin secretion is likely to be the main cause for our findings.
Authors: P Galvin; G Ward; J Walters; R Pestell; M Koschmann; A Vaag; I Martin; J D Best; F Alford Journal: Diabet Med Date: 1992-12 Impact factor: 4.359
Authors: Laura J Scott; Lori L Bonnycastle; Cristen J Willer; Andrew G Sprau; Anne U Jackson; Narisu Narisu; William L Duren; Peter S Chines; Heather M Stringham; Michael R Erdos; Timo T Valle; Jaakko Tuomilehto; Richard N Bergman; Karen L Mohlke; Francis S Collins; Michael Boehnke Journal: Diabetes Date: 2006-09 Impact factor: 9.461
Authors: Coleen M Damcott; Toni I Pollin; Laurie J Reinhart; Sandra H Ott; Haiqing Shen; Kristi D Silver; Braxton D Mitchell; Alan R Shuldiner Journal: Diabetes Date: 2006-09 Impact factor: 9.461
Authors: Abbas E Kitabchi; Marinella Temprosa; William C Knowler; Steven E Kahn; Sarah E Fowler; Steven M Haffner; Reuben Andres; Christopher Saudek; Sharon L Edelstein; Richard Arakaki; Mary Beth Murphy; Harry Shamoon Journal: Diabetes Date: 2005-08 Impact factor: 9.461
Authors: Steve E Humphries; David Gable; Jackie A Cooper; Helen Ireland; Jeffrey W Stephens; Steven J Hurel; Ka Wah Li; Jutta Palmen; Michelle A Miller; Francesco P Cappuccio; Robert Elkeles; Ian Godsland; George J Miller; Philippa J Talmud Journal: J Mol Med (Berl) Date: 2006-12 Impact factor: 4.599
Authors: Jill P Crandall; William C Knowler; Steven E Kahn; David Marrero; Jose C Florez; George A Bray; Steven M Haffner; Mary Hoskin; David M Nathan Journal: Nat Clin Pract Endocrinol Metab Date: 2008-05-20
Authors: Daruneewan Warodomwichit; Donna K Arnett; Edmond K Kabagambe; Michael Y Tsai; James E Hixson; Robert J Straka; Michael Province; Ping An; Chao-Qiang Lai; Ingrid Borecki; Jose M Ordovas Journal: J Nutr Date: 2009-01-13 Impact factor: 4.798